Published on: Jun 24, 2016 at MPR

FDA Grants Napabucasin Orphan Drug Status for Gastric Cancer

By : MPR

Boston Biomedical announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for its investigational compound, napabucasin, for the treatment of gastric cancer, including gastroesophageal junction (GEJ) cancer.

Read More